WallStSmart

Bio-Rad Laboratories Inc (BIO-B)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 1296% more annual revenue ($35.48B vs $2.54B). MDT leads profitability with a 13.0% profit margin vs -85.2%. BIO-B appears more attractively valued with a PEG of 1.21. MDT earns a higher WallStSmart Score of 56/100 (C).

BIO-B

Hold

37

out of 100

Grade: F

Growth: 2.0Profit: 3.5Value: 6.7Quality: 8.5
Piotroski: 5/9Altman Z: 2.31

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIO-B.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIO-B2 strengths · Avg: 9.5/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.209/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

BIO-B4 concerns · Avg: 1.8/10
Return on EquityProfitability
-27.5%2/10

ROE of -27.5% — below average capital efficiency

Revenue GrowthGrowth
-4.2%2/10

Revenue declined 4.2%

EPS GrowthGrowth
-83.0%2/10

Earnings declined 83.0%

Profit MarginProfitability
-85.2%1/10

Currently unprofitable

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : BIO-B

The strongest argument for BIO-B centers on Price/Book, Debt/Equity. PEG of 1.21 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : BIO-B

The primary concerns for BIO-B are Return on Equity, Revenue Growth, EPS Growth.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

BIO-B profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

BIO-B carries more volatility with a beta of 0.94 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bio-Rad Laboratories Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?